Cyclacel Pharmaceuticals Inc. (CYCC)
Oncology Corporate Profile
- Products & Overview
- Recent News
HQ Location
200 Connell Drive, Suite 1500Berkeley Heights, NJ 07922
Company Description
Cyclacel Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.
Website: http://www.cyclacel.com
Commercial Products
| Brand | Generic | Indication |
|---|---|---|
| Numoisyn™ Liquid | Numoisyn Liquid is indicated for the treatment of symptoms of dry mouth. Numoisyn Liquid relieves the symptoms of dry mouth by enhancing swallowing, improving speech mechanics, and lubricating the oral cavity like natural saliva. Numoisyn Liquid may be used to replace natural saliva when salivary glands are damaged or not functioning. The viscosity is similar to that of natural saliva. | |
| Numoisyn™ Lozenges | Numoisyn Lozenges are indicated for the treatment of xerostomia (dry mouth). Numoisyn Lozenges provide temporary relief of dry mouth due to damaged salivary function. Numoisyn Lozenges are formulated to support the natural protection of teeth provided by saliva so that no damage occurs to teeth with repeated use of the lozenges. | |
| Xclair™ Cream | Xclair Cream is indicated to manage and relieve the burning, itching, and pain experienced with radiation dermatitis. Xclair Cream may be used to relieve the pain of firstand second-degree burns. |
Pipeline Products
- Brand
- Generic
- Investigational
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| sapacitabine / CYC682 | antimetabolite (oral) | Acute Myelogenous Leukemia (AML) | II | |
| sapacitabine / CYC682 | antimetabolite (oral) | Myelodysplastic Syndrome (MDS) | II | |
| seliciclib / CYC202 | cyclin-dependent kinase inhibitor (oral) | Nasopharyngeal cancer | II | |
| sapacitabine / CYC682 | antimetabolite (oral) | Non Small Cell Lung Cancer (NSCLC) | II | |
| seliciclib / CYC202 | cyclin-dependent kinase inhibitor (oral) | Non Small Cell Lung Cancer (NSCLC) | II | |
| CYC116 | aurora kinase/VEGFR2 inhibitor | Various cancer types | I | |
| sapacitabine (+ seliciclib) / CYC682 (+ CYC202) | antimetabolite (oral)/cyclin-dependent kinase inhibitor (oral) | Various cancer types | I |
View additional information on product candidates here »
Recent News Headlines
[GlobeNewswire] - BERKELEY HEIGHTS, N.J. -- Cyclacel Pharmaceuticals, Inc. , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders , today reported that it has received a request from a holder of at least 10% of its 6% Convertible Exchangeable Preferred Stock that the Company call a special meeting of its holders of Preferred Stock to elect two directors to fill the vacancies on the Company's board of directors.
[GlobeNewswire] - BERKELEY HEIGHTS, N.J. -- Cyclacel Pharmaceuticals, Inc. , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the second quarter of 2010.
[GlobeNewswire] - BERKELEY HEIGHTS, N.J. -- Cyclacel Pharmaceuticals, Inc. , will announce second quarter 2010 financial results on Thursday, August 5, 2010. The Company will host a conference call and live webcast at 4:30 pm Eastern time on the same day.
[GlobeNewswire] - CALGARY, Alberta -- Skymark Research, a leading provider of small- and micro-cap independent investment research, today initiated coverage on Cyclacel Pharmaceuticals, Inc. .
[GlobeNewswire] - BERKELEY HEIGHTS, N.J. -- Cyclacel Pharmaceuticals, Inc. , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S.
(MarketWatch) July 1, 2010 – Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's sapacitabine (CYC682) product candidate for the treatment of both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
[GlobeNewswire] - BERKELEY HEIGHTS, N.J. -- Cyclacel Pharmaceuticals, Inc. , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company has been added to the Russell Microcap Index.
[GlobeNewswire] - BERKELEY HEIGHTS, N.J. -- Cyclacel Pharmaceuticals, Inc. , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it filed its Answer and Counterclaims to the declaratory judgment complaint filed by Celgene Corporation.
(MarketWatch) June 18, 2010 - Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it filed its Answer and Counterclaims to the declaratory judgment complaint filed by Celgene Corporation.
[Indie Research] - Seattle-based cancer treatment firm Cell Therapeutics soared higher by more than 20% on Friday after the company announced positive data from its Pixuvri trial in patients with relapsed or refractory, aggressive non-Hodgkin's lymphoma.
[GlobeNewswire] - BERKELEY HEIGHTS, N.J. -- Cyclacel Pharmaceuticals, Inc. announced today interim response data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes that have failed hypomethylating agents.
(MarketWatch) June 7, 2010 - Cyclacel Pharmaceuticals, Inc. announced today interim response data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes (MDS) that have failed hypomethylating agents.
[GlobeNewswire] - BERKELEY HEIGHTS, N.J. -- Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
(Yahoo! Finance) May 21, 2010 - Cyclacel Pharmaceuticals, Inc. announced that new interim data from an ongoing, multicenter, Phase 2 clinical trial of oral sapacitabine, the Company's lead product candidate, will be presented at an oral poster discussion during the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on Monday, June 7, 2010.
BERKELEY HEIGHTS, N.J. -- Cyclacel Pharmaceuticals, Inc. , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the first quarter ended March 31, 2010.